Literature DB >> 32390158

Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B.

Rachel Rayment1, Elizabeth Chalmers2, Katherine Forsyth3, Richard Gooding4, Anne M Kelly5, Susan Shapiro6, Kate Talks7, Oliver Tunstall8, Tina Biss7.   

Abstract

Entities:  

Year:  2020        PMID： 32390158     DOI： 10.1111/bjh.16704

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

Review 1.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

2.  Seroprevalence to adeno-associated virus type 6 in people with hemophilia B from a UK adult cohort.

Authors:  Sara Boyce; Izabela James; Savita Rangarajan; Nicola Curry; Catherine Bagot; Steven Austin; Mike Laffan; Sarah Mangles; Kandiah Chandrakumaran; Carina Mundy
Journal:  Res Pract Thromb Haemost       Date:  2022-06-03

3.  Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.

Authors:  Kate Khair; Elizabeth Chalmers; Thuvia Flannery; Annabel Griffiths; Felicity Rowley; Guillermo Tobaruela; Pratima Chowdary
Journal:  Ther Adv Hematol       Date:  2021-04-30

4.  Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).

Authors:  Robert Klamroth; Kingsley Hampton; Sonata Saulyte Trakymienė; Lars Korsholm; Manuel Carcao
Journal:  Patient Prefer Adherence       Date:  2021-11-04       Impact factor: 2.711

5.  Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.

Authors:  Anouk A M T Donners; Carin M A Rademaker; Lisanne A H Bevers; Alwin D R Huitema; Roger E G Schutgens; Toine C G Egberts; Kathelijn Fischer
Journal:  Clin Pharmacokinet       Date:  2021-08-13       Impact factor: 5.577

6.  Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.

Authors:  Antonio Coppola; Massimo Franchini; Giovanni Pappagallo; Alessandra Borchiellini; Raimondo De Cristofaro; Angelo Claudio Molinari; Rita Carlotta Santoro; Cristina Santoro; Annarita Tagliaferri
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

7.  Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study.

Authors:  Idaira Rodriguez-Santana; Pronabesh DasMahapatra; Tom Burke; Zalmai Hakimi; José Bartelt-Hofer; Jameel Nazir; Jamie O'Hara
Journal:  Orphanet J Rare Dis       Date:  2022-04-04       Impact factor: 4.123

Review 8.  Efmoroctocog Alfa: A Review in Haemophilia A.

Authors:  James E Frampton
Journal:  Drugs       Date:  2021-11-07       Impact factor: 9.546

9.  The bleeding phenotype in people with nonsevere hemophilia.

Authors:  Fabienne R Kloosterman; Anne-Fleur Zwagemaker; Catherine N Bagot; Erik A M Beckers; Giancarlo Castaman; Marjon H Cnossen; Peter W Collins; Charles Hay; Michel Hof; Britta Laros-van Gorkom; Frank W G Leebeek; Christoph Male; Karina Meijer; Ingrid Pabinger; Susan Shapiro; Michiel Coppens; Karin Fijnvandraat; Samantha C Gouw
Journal:  Blood Adv       Date:  2022-07-26

Review 10.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.